Skip to content
Review Open access

Transformative Pathways in Oncology: A Systematic Review and Framework for AI-Driven Cancer Progression Risk Analytics and Prediction

Aug 2026 · Information · 0 citations · 84 references

TL;DR

The AI-driven cancer progression risk analytics framework (AI CanPRAF) is developed, which integrates AI taxonomies, imaging phenotypes, clinical context, progression analytics and decision support into one clinically oriented model.

Abstract

Artificial intelligence (AI) has emerged as a transformative analytical paradigm for modelling cancer progression using medical imaging and complementary clinical data. This systematic review collates and analyses AI-powered systems and techniques for cancer progression risk analytics and prediction. It provides an empirical examination of algorithmic approaches, imaging-derived feature domains, and clinical metrics that underpin progression prediction. Following the PRISMA 2020 reporting guidance, empirical English-language studies published between 2020 and the final search cutoff date of 15 May 2026 were identified from PubMed, EBSCOhost, Google Scholar and Web of Science. Forty (40) eligible studies spanning diverse cancer types were included, appraised using the MMAT and synthesised narratively. The evidence shows that both classical machine learning models and deep learning architectures are widely used to extract predictive information from radiological data. Radiomic descriptors of intratumoural heterogeneity, tumour morphology, functional imaging biomarkers and multiscale transform-based features consistently demonstrate strong associations with disease progression. Imaging-derived features were linked to clinically meaningful progression endpoints, including progression-free survival, disease-free survival, recurrence and metastasis, while clinical and molecular covariates supported risk stratification. This study further develops the AI-driven cancer progression risk analytics framework (AI CanPRAF), which integrates AI taxonomies, imaging phenotypes, clinical context, progression analytics and decision support into one clinically oriented model. The results demonstrate the growing role of multimodal AI systems in the development of clinically grounded cancer progression analytics and prediction solutions.

Read PDF

Similar papers

Review Open access Aug 2026

Feature-Centric AI for Breast Cancer Metastasis Analytics: A Systematic Review and Evidence-Based Framework for Feature Engineering and Multimodal Integration

The study crafts an evidence-informed conceptual 5Fs framework comprising feature extraction or generation, feature preparation and transformation, feature selection and dimensionality reduction, feature construction and integration, and feature interpretability and explainability that highlights the feature-centric na...

Wellington Kanyongo, B. Chimbo · 0 citations
Review Open access Sep 2026

Computational and AI-Enabled Imaging Biomarkers for Predicting and Assessing Immunotherapy Response in Oral Squamous Cell Carcinoma: A Systematic Review with Functional Meta-Synthesis

Background/Objectives: Computational and artificial intelligence (AI)-enabled imaging biomarkers are increasingly being investigated for immunotherapy-response assessment in oral squamous cell carcinoma (OSCC), but the evidence is heterogeneous. This systematic review identified, critically appraised, and synthesized i...

Carlos M. Ardila, A. M. Vivares-Builes, Eliana Pineda-Vélez · 0 citations
Review Open access Aug 2026

Machine learning and AI for cancer research and care: a review of applications, limitations, and future directions

This review synthesizes key developments in ML for oncology, covering foundational algorithms alongside emerging approaches, and describes future directions, including federated learning, graph neural networks, longitudinal modeling, and integration of real-world and wearable data to support precision oncology.

Kanishk Yadav, Taneesha Gupta · 0 citations
Review Aug 2026

AI-Driven Multiomics Biomarkers for Precision Oncology: Navigating the Translational Gap and Regulatory Hurdles.

This review critically evaluates how advanced technologies operating in an integrated manner facilitate precision oncology by supporting fields such as genomics, transcriptomics, proteomics, metabolomics, and radiomics and provides an integrative roadmap for modern, multiomics-driven biomarker approaches in precision o...

Ujwal Havelikar, Atharva A. Shinde, Hrushikesh Mhaismale et al. · 0 citations
Review Open access 2026

Comparative Evaluation of AI-Based and Non-AI Genomic Biomarkers for Predicting Lung Cancer Treatment Response: A Systematic Review

Conventional genomic biomarkers remain central to current lung cancer treatment decisions because of their established clinical validity, and AI-based genomic models show promise for improving prediction and patient stratification, but their clinical utility remains uncertain without stronger prospective validation.

F. Siddique, M. Shehata, M. Ghazal et al. · 0 citations
#artificial intelligence Review Open access Sep 2026

Decoding cancer with artificial intelligence: Transforming research, diagnosis, and therapy with future insights

Emerging AI paradigms offer future-ready frameworks for personalized, privacy-preserving oncology care and multi-omics integration powered by AI enables the discovery of robust biomarkers for diagnosis, prognosis, and therapy response prediction.

M. Anwer, Krupa R. Bhaliya, Ming Q. Wei · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.